LENSAR, Inc. (LNSR)
| Market Cap | 36.37M |
| Revenue (ttm) | 42.16M |
| Net Income (ttm) | -14.38M |
| Shares Out | 11.40M |
| EPS (ttm) | -1.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,659 |
| Open | 3.275 |
| Previous Close | 3.180 |
| Day's Range | 3.145 - 3.326 |
| 52-Week Range | 1.800 - 5.300 |
| Beta | 0.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2024 |
About LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a ... [Read more]
Financial Performance
In 2023, LENSAR's revenue was $42.16 million, an increase of 19.25% compared to the previous year's $35.36 million. Losses were -$14.38 million, -27.79% less than in 2022.
Financial StatementsNews
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hi...
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR Reports Third Quarter 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR Reports Second Quarter 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of catara...
LENSAR to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR Reports First Quarter 2023 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR to Present at Two Upcoming Investor Conferences
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatmen...
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla.
LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022
ORLANDO, Fla.
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
First Patients Treated with LENSAR's® ALLY™ Adaptive Cataract Treatment System
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
Why Lensar Shares Are Trading Higher Today
The FDA granted 510(k) clearance to Lensar Inc's (NASDAQ: LNSR) next-generation ALLY Adaptive Cataract Treatment System (ALLY System). ALLY is the first FDA-cleared platform to enable cataract surgeon...
LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...
LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment ...